drugset / Trial / NCT00648414

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

NCT00648414

Phase 1 Terminated 12 enrolled Mylan Pharmaceuticals Inc
RandomizedFactorialOpen-labelOther

Summary

The objective of this study was to investigate the effect of clinical procedures on the drug delivery of Fentanyl Transdermal Systems, 25 mcg/h manufactured for Mylan Pharmaceuticals Inc. by Mylan Technologies Inc., and Duragesic, 25 mcg/h manufactured for Janssen Pharmaceutica by ALZA Corporation.

Timeline

Start
2006-10
Primary completion
2006-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 25 ug Other

Indications

No indication recorded.